focus -WSS

focus

author：Wikipedia 2025-09-27 12:55:23 - browse：47

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： The Harvard botanist who searched for psychedelics in the Amazon

focus

knowledge

focus

WSS

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

In utero gene editing: an explainer

STAT readers on older presidents, polypills, Medicare, and more

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Obesity drugs seen as possible treatment for liver disease MASH

knowledge

focus

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Timeline: Key moments in fight for gay rights

Novavax promises a turnaround & Lilly roils the obesity market

NIH study of ME/CFS points to clear biological hallmarks

Medical records are filled with copy

PBM reform efforts get punted in Congress

How to save PrEP access — and even expand it

The thinking behind the controversial eating disorder chatbot Tessa

Hepatitis C has a cure — but many Americans still lack access to it

Biogen nominates mother of director’s child to replace him on board

hotspot

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Xenotransplantation trials will require adjusting expectations, experts say

Community Health Systems hospitals under DOJ investigation

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

He's a Nobel laureate. Critics say he was misleading on Covid

focus

knowledge

focus

leisure time